Location History:
- Riehen, CH (2010 - 2014)
- Redwood City, CA (US) (2017)
Company Filing History:
Years Active: 2010-2017
Title: Innovations of Michael Foulkes in Chemical Processes
Introduction
Michael Foulkes is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of chemistry, particularly in the development of processes for preparing complex chemical compounds. With a total of four patents to his name, Foulkes has demonstrated a commitment to advancing pharmaceutical chemistry.
Latest Patents
Foulkes' latest patents include a chemical process for preparing spiroindolones and intermediates thereof. This invention relates to processes and intermediates useful for the manufacture of spiroindolone compounds, such as (1'R,3′S)-5,7′-dichloro-6′-fluoro-3′-methyl-2′,3′,4′,9′-tetrahydrospiro[indoline-3,1′-pyrido[3,4-b]indol]-2-one and its salts, hydrates, and solvates. Another significant patent involves a process for the preparation of optically active compounds using transfer hydrogenation. This catalytic process is aimed at preparing optically active compounds and converting them into desired drug substances, specifically focusing on the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol through asymmetric catalytic reduction and transfer hydrogenation.
Career Highlights
Michael Foulkes is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to contribute to innovative solutions in drug development and chemical processes. His expertise in the field has positioned him as a valuable asset to the company.
Collaborations
Foulkes has collaborated with notable colleagues, including Christian Mathes and Martin Kesselgruber. These collaborations have further enhanced his research and development efforts in the pharmaceutical industry.
Conclusion
Michael Foulkes is a distinguished inventor whose work in chemical processes has led to significant advancements in the field. His contributions, particularly in the preparation of spiroindolones and optically active compounds, reflect his dedication to innovation in pharmaceutical chemistry.